ES2986557T3 - Enzimas para el análisis de glucanos - Google Patents
Enzimas para el análisis de glucanos Download PDFInfo
- Publication number
- ES2986557T3 ES2986557T3 ES18728577T ES18728577T ES2986557T3 ES 2986557 T3 ES2986557 T3 ES 2986557T3 ES 18728577 T ES18728577 T ES 18728577T ES 18728577 T ES18728577 T ES 18728577T ES 2986557 T3 ES2986557 T3 ES 2986557T3
- Authority
- ES
- Spain
- Prior art keywords
- sialidase
- seq
- amino acid
- glycoprotein
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004458 analytical method Methods 0.000 title claims description 12
- 102000004190 Enzymes Human genes 0.000 title abstract description 67
- 108090000790 Enzymes Proteins 0.000 title abstract description 67
- 150000004676 glycans Chemical class 0.000 title description 10
- 102000005348 Neuraminidase Human genes 0.000 claims abstract description 201
- 108010006232 Neuraminidase Proteins 0.000 claims abstract description 201
- 239000000203 mixture Substances 0.000 claims abstract description 111
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 56
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 45
- 101710118538 Protease Proteins 0.000 claims abstract description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 96
- 229920001184 polypeptide Polymers 0.000 claims description 93
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 93
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 61
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 19
- 229930182817 methionine Natural products 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 16
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 108090001090 Lectins Proteins 0.000 claims description 10
- 102000004856 Lectins Human genes 0.000 claims description 10
- 239000002523 lectin Substances 0.000 claims description 10
- 241000702462 Akkermansia muciniphila Species 0.000 claims description 7
- 230000003301 hydrolyzing effect Effects 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 5
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 abstract description 5
- 239000004365 Protease Substances 0.000 abstract description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 5
- 102000005744 Glycoside Hydrolases Human genes 0.000 abstract description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 abstract description 2
- 238000013519 translation Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 68
- 239000000758 substrate Substances 0.000 description 50
- 150000001413 amino acids Chemical class 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 34
- 241000194025 Streptococcus oralis Species 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- 125000005629 sialic acid group Chemical group 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 23
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 23
- 239000000872 buffer Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 18
- 102000013361 fetuin Human genes 0.000 description 14
- 108060002885 fetuin Proteins 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 13
- 230000002255 enzymatic effect Effects 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 102000004366 Glucosidases Human genes 0.000 description 12
- 108010056771 Glucosidases Proteins 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 229920001503 Glucan Polymers 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 230000007062 hydrolysis Effects 0.000 description 10
- 238000006460 hydrolysis reaction Methods 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 108010008165 Etanercept Proteins 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 description 7
- 229940073621 enbrel Drugs 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000003656 tris buffered saline Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 101710165315 Sialidase A Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 241000702460 Akkermansia Species 0.000 description 3
- 241000193468 Clostridium perfringens Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- -1 sialic acid hexose Chemical class 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101150002621 EPO gene Proteins 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002169 hydrotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229940035567 orencia Drugs 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 102000002014 alpha-N-Acetylgalactosaminidase Human genes 0.000 description 1
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 150000002402 hexoses Chemical group 0.000 description 1
- 101150026046 iga gene Proteins 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010084553 jacalin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24057—O-Sialoglycoprotein endopeptidase (3.4.24.57), i.e. glycoprotease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/952—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from bacteria
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1708471.6A GB201708471D0 (en) | 2017-05-26 | 2017-05-26 | Polypeptide |
| GBGB1708476.5A GB201708476D0 (en) | 2017-05-26 | 2017-05-26 | Tools for glycan analysis |
| GBGB1806655.5A GB201806655D0 (en) | 2018-04-24 | 2018-04-24 | Polypeptide |
| PCT/EP2018/063833 WO2018215657A1 (en) | 2017-05-26 | 2018-05-25 | Enzymes for glycan analysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2986557T3 true ES2986557T3 (es) | 2024-11-11 |
Family
ID=62492612
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18728577T Active ES2986557T3 (es) | 2017-05-26 | 2018-05-25 | Enzimas para el análisis de glucanos |
| ES18728576T Active ES2986910T3 (es) | 2017-05-26 | 2018-05-25 | Proteasa y polipéptido de unión para o-glicoproteínas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18728576T Active ES2986910T3 (es) | 2017-05-26 | 2018-05-25 | Proteasa y polipéptido de unión para o-glicoproteínas |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11584922B2 (enExample) |
| EP (2) | EP3630967B8 (enExample) |
| JP (3) | JP7195008B2 (enExample) |
| KR (2) | KR102609790B1 (enExample) |
| CN (2) | CN111183221B (enExample) |
| AU (2) | AU2018272984B2 (enExample) |
| CA (2) | CA3063828A1 (enExample) |
| DK (2) | DK3630968T3 (enExample) |
| ES (2) | ES2986557T3 (enExample) |
| FI (2) | FI3630968T3 (enExample) |
| IL (2) | IL270950B2 (enExample) |
| PL (2) | PL3630967T3 (enExample) |
| PT (2) | PT3630967T (enExample) |
| WO (2) | WO2018215656A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2986557T3 (es) * | 2017-05-26 | 2024-11-11 | Genovis Ab | Enzimas para el análisis de glucanos |
| AU2020301037A1 (en) * | 2019-07-03 | 2022-02-03 | Palleon Pharmaceuticals Inc. | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same |
| CN112795583A (zh) * | 2020-11-16 | 2021-05-14 | 上海大学 | 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法 |
| WO2023114931A1 (en) * | 2021-12-15 | 2023-06-22 | Danisco Us Inc. | Compositions and methods involving proteases specific for mannose-modified proteins |
| WO2024118481A1 (en) * | 2022-11-28 | 2024-06-06 | Amgen Inc. | Method of processing etanercept |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6720165B2 (en) | 2001-06-14 | 2004-04-13 | Zyomix, Inc. | Methods for making antibody fragments and compositions resulting therefrom |
| US7807174B2 (en) * | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| GB0624874D0 (en) | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| WO2009129086A2 (en) | 2008-04-18 | 2009-10-22 | New England Biolabs, Inc. | Endoglycosidases that cleave o-linked glycans |
| EP2166085A1 (en) | 2008-07-16 | 2010-03-24 | Suomen Punainen Risti Veripalvelu | Divalent modified cells |
| US20100261185A1 (en) | 2009-03-27 | 2010-10-14 | Life Technologies Corporation | Labeled enzyme compositions, methods and systems |
| GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| WO2016003795A1 (en) | 2014-07-02 | 2016-01-07 | New England Biolabs, Inc. | Universal n-glycan binding reagent |
| WO2017052433A1 (en) | 2015-09-24 | 2017-03-30 | Saab Ab | A modular fluid actuator system |
| WO2017134274A1 (en) | 2016-02-04 | 2017-08-10 | Ulrich Von Pawel-Rammingen | New streptococcal proteases |
| ES2986557T3 (es) * | 2017-05-26 | 2024-11-11 | Genovis Ab | Enzimas para el análisis de glucanos |
-
2018
- 2018-05-25 ES ES18728577T patent/ES2986557T3/es active Active
- 2018-05-25 PL PL18728576.2T patent/PL3630967T3/pl unknown
- 2018-05-25 EP EP18728576.2A patent/EP3630967B8/en active Active
- 2018-05-25 KR KR1020197036837A patent/KR102609790B1/ko active Active
- 2018-05-25 AU AU2018272984A patent/AU2018272984B2/en active Active
- 2018-05-25 PT PT187285762T patent/PT3630967T/pt unknown
- 2018-05-25 CN CN201880050251.7A patent/CN111183221B/zh active Active
- 2018-05-25 WO PCT/EP2018/063832 patent/WO2018215656A1/en not_active Ceased
- 2018-05-25 WO PCT/EP2018/063833 patent/WO2018215657A1/en not_active Ceased
- 2018-05-25 FI FIEP18728577.0T patent/FI3630968T3/fi active
- 2018-05-25 CA CA3063828A patent/CA3063828A1/en active Pending
- 2018-05-25 KR KR1020197036845A patent/KR102608876B1/ko active Active
- 2018-05-25 JP JP2019565188A patent/JP7195008B2/ja active Active
- 2018-05-25 CN CN201880050240.9A patent/CN111183220B/zh active Active
- 2018-05-25 IL IL270950A patent/IL270950B2/en unknown
- 2018-05-25 PT PT187285770T patent/PT3630968T/pt unknown
- 2018-05-25 US US16/616,827 patent/US11584922B2/en active Active
- 2018-05-25 DK DK18728577.0T patent/DK3630968T3/da active
- 2018-05-25 FI FIEP18728576.2T patent/FI3630967T3/fi active
- 2018-05-25 EP EP18728577.0A patent/EP3630968B8/en active Active
- 2018-05-25 IL IL270949A patent/IL270949B2/en unknown
- 2018-05-25 PL PL18728577.0T patent/PL3630968T3/pl unknown
- 2018-05-25 JP JP2019565178A patent/JP2020521460A/ja active Pending
- 2018-05-25 DK DK18728576.2T patent/DK3630967T3/da active
- 2018-05-25 CA CA3063815A patent/CA3063815A1/en active Pending
- 2018-05-25 US US16/616,872 patent/US12448614B2/en active Active
- 2018-05-25 ES ES18728576T patent/ES2986910T3/es active Active
- 2018-05-25 AU AU2018272400A patent/AU2018272400B2/en active Active
-
2022
- 2022-12-22 US US18/145,807 patent/US20230212543A1/en active Pending
-
2023
- 2023-04-13 JP JP2023065981A patent/JP7557896B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2986557T3 (es) | Enzimas para el análisis de glucanos | |
| ES2627334T3 (es) | Endoglucosidasa de streptococcus pyogenes y métodos para usarla | |
| US11098298B2 (en) | Method for recombinant production of horseshoe crab Factor C protein in protozoa | |
| ES2896489T3 (es) | Composiciones y procedimientos para el tratamiento de la enfermedad esprúe celíaco | |
| JP2019135252A (ja) | セリアックスプルー病を処置するための組成物および方法 | |
| Takeshita et al. | Determination of the complete cDNA sequence, construction of expression systems, and elucidation of fibrinolytic activity for Tapes japonica lysozyme | |
| Kim et al. | Expression, purification and characterization of soluble recombinant peptidyl-prolyl cis/trans isomerase from Vibrio anguillarum | |
| Andrianova et al. | Role of α-helical domains in functioning of ATP-dependent Lon protease of Escherichia coli | |
| US9545431B1 (en) | Isolated recombinant cDNA | |
| Kudzhaev et al. | The effect of mutations in the inserted domain of ATP-dependent Lon protease from E. coli on the enzyme function |